IMPACT OF COLD ISCHEMIA TIME ON THE EXPRESSION OF ER, PR, AND KI-67 IN BREAST CANCER USING IMMUNOHISTOCHEMISTRY
Main Article Content
Abstract
Background: Immunohistochemical (IHC) assessment of estrogen receptor (ER), progesterone receptor (PR), and Ki-67 plays an essential role for breast cancer diagnosis, prognostication, and treatment decision-making. Because these biomarkers are localized in the nucleus, the accuracy of IHC results depends heavily on antigen preservation. Cold ischemia time is a critical pre-analytical factor, and prolonged delays before fixation may cause protein degradation, attenuated nuclear staining, and misclassification of biomarker status. Objectives: To investigate the impact of cold ischemia time on ER, PR and Ki-67 expression in breast cancer using immunohistochemistry. Subjects and Methods: This exploratory study was conducted on purposively selected breast cancer tissue specimens that met inclusion criteria. Samples were subdivided and subjected to cold ischemia intervals ranging from less than 1 hour to 8 hours before fixation in 10% neutral-buffered formalin (10% NBF; ~4% formaldehyde, phosphate buffer, pH 7.0). After fixation for 8–32 h and tissue processing, sectioned at 3–4 µm, immunohistochemistry for ER, PR, and Ki-67 was performed. Nuclear staining intensity, proportion of positive cells, and rate of nuclear degeneration were analyzed to evaluate the impact of delayed fixation. Results: For ER, the mean staining intensity began to decline at 2 hours, the mean proportion of positive nuclei decreased at 3 hours, and the mean rate of nuclear degeneration increased at 2 hours. For PR, the mean staining intensity decreased at 2 hours, the mean proportion of positive nuclei decreased at 3 hours, and nuclear degeneration increased at 2 hours, followed by a slight reduction at 4 hours and a subsequent increase at 6 hours. For Ki-67, nuclear degeneration began to increase at 2 hours, whereas the proportion of positive nuclei showed only minimal, nonsignificant variation. Conclusions: Prolonged cold ischemia time decreased the staining intensity and proportion of ER and PR expression and increased the rate of nuclear degeneration for ER, PR, and Ki-67. Although the proportion of Ki-67–positive cells was minimally affected, the downward trend in nuclear quality underscores the need for strict preanalytic control. Preanalytic deviations increase the risk of ER/PR under- or over-calling, misclassification of Luminal subtypes, and inappropriate endocrine or chemotherapy decisions. These findings demonstrate a statistically significant association between cold ischemia time and attenuation of ER/PR expression and emphasize adherence ASCO/CAP recommendations: initiate fixation within ≤1 hour of excision to preserve the reliability of IHC.
Article Details
Keywords
cold ischemia time, immunohistochemistry, estrogen receptor (ER), progesterone receptor (PR), Ki-67, breast cancer.
References
2. Yildiz-Aktas IZ, Dabbs DJ, Bhargava R. The effect of cold ischemic time on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast carcinoma. Mod Pathol. 2012;25(8):1098-1105. doi:10.1038/ modpathol.2012.59.
3. Pekmezci M, Szpaderska A, Osipo C, Erşahin C. The Effect of Cold Ischemia Time and/or Formalin Fixation on Estrogen Receptor, Progesterone Receptor, and Human Epidermal Growth Factor Receptor-2 Results in Breast Carcinoma. Patholog Res Int. 2012;2012:947041. doi:10.1155/2012/947041.
4. Neumeister VM, Anagnostou V, Siddiqui S, et al. Quantitative assessment of effect of preanalytic cold ischemic time on protein expression in breast cancer tissues. J Natl Cancer Inst. 2012;104(23):1815-1824. doi:10.1093/jnci/ djs438.
5. Wang X, O'Brien ME, Yu J, et al. Prolonged Cold Ischemia Induces Necroptotic Cell Death in Ischemia-Reperfusion Injury and Contributes to Primary Graft Dysfunction after Lung Transplantation. Am J Respir Cell Mol Biol. 2019;61(2): 244-256. doi:10.1165/rcmb.2018-0207OC.
6. Khoury T. Delay to Formalin Fixation (Cold Ischemia Time) Effect on Breast Cancer Molecules. Am J Clin Pathol. 2018;149(4):275-292. doi:10.1093/ajcp/aqx164